百日咳患儿血清PT-IgG水平相关因素分析

doi:10.12372/jcp.2022.21e0566

Abstract

Abstract: Objective To investigate the relative factors of serum pertussis toxin antibodies (PT-IgG) in children with pertussis.Methods Clinical data of children hospitalized with pertussis from April 1, 2018 to July 31, 2019 were retrospectively analyzed. To analyze the influence of different course of disease, pertussis vaccine dose, onset age and disease severity on PT-IgG level in children with pertussis. Result A total of 638 children were included. In the unvaccinated group, 313 patients (177 boys and 136 girls) had a median age of 78.0 (52.0-125.0) days. In the vaccination group, there were 325 patients (163 boys and 162 girls) with a median age of 232.0 (144.0-483.0) days. There were statistically significant differences in the distribution of PT-IgG levels among different disease course groups at sampling (≤14d, 15-21d, >21d) in the unvaccinated group (P<0.01). The proportion of PT-IgG≥80 IU/mL was higher in patients with disease course >21 days. There was significant difference in PT IgG level between different vaccine groups (P<0.01). The proportion of PT-IgG≥80 IU/mL was higher in patients with disease course of 15~21 days and >21 days. There were statistically significant differences in PT-IgG levels between groups receiving different doses of vaccine (P<0.01). The levels of PT-IgG gradually increased with the increase of vaccine doses. In the unvaccinated group, no matter in the severe group or the normal group, the difference of PT-IgG level among different disease course groups at sampling was statistically significant (P<0.05). In the inoculation group, the difference of PT-IgG levels among different disease course groups at sampling in the normal group was statistically significant (P<0.05).Conclusions The level of PT-IgG in children with acute infection of Bordetella pertussis in China was not high, and 59.9% of them had a PT-IgG level lower than 20IU/mL. PT-IgG levels were affected by the dose of vaccine and the course of disease at the time of sampling.

Key words: pertussis, vaccine, pertussis toxin antibody

GAN Chuan, WU Xiaoying, XU Hongmei. Analysis of related factors of serum PT-IgG concentration in children with pertussis diagnosed by etiology[J].Journal of Clinical Pediatrics, 2022, 40(4): 263-267.

Figures/Tables 3

References 15

[1]	Melvin JA, Scheller EV, Miller JF, et al. Bordetella pertussis pathogenesis: current and future challenges[J]. Nat Rev Microbiol. 2014, 12(4):274-288. doi: 10.1038/nrmicro3235
[2]	Cherry JD, Heininger U. Text Book of Pediatric Infectious Diseases[M]. 5th Edit, America: Saunders, 2003: 1588-1608.
[3]	Subissi L, Rodeghiero C, Martini H, et al. Assessment of IgA anti-PT and IgG anti-ACT reflex testing to improve Bordetella pertussis serodiagnosis in recently vaccinated subjects[J]. Clin Microbiol Infect, 2020, 26(5): 645.e1-645-e8. doi: 10.1016/j.cmi.2019.10.001
[4]	彭晓康, 唐丽, 卫慧静, 等. 835例百日咳患儿PTIgG水平的影响因素分析[J]. 中国妇幼健康研究, 2020, 31(6):712-716.
[5]	中华医学会儿科学分会感染学组, 《中华儿科杂志》编辑委员会. 中国儿童百日咳诊断及治疗建议[J]. 中华儿科杂志, 2017, 55(8):568-572.
[6]	吴小英, 甘川. 婴幼儿重症百日咳死亡相关因素分析[J]. 临床儿科杂志, 2020, 38(6):432-437.
[7]	Munoz JJ, Arai H, Bergman RK, et al. Biological activities of crystalline pertussigen from Bordetella pertussis[J]. Infect Immun, 1981, 33(3):820-826. doi: 10.1128/iai.33.3.820-826.1981 pmid: 6269999
[8]	Morse SI, Morse JH. Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of Bordetella pertussis[J]. J Exp Med. 1976, 143(6):1483-1502. doi: 10.1084/jem.143.6.1483 pmid: 58054
[9]	Hewlett EL, Burns DL, Cotter PA, et al. Pertussis pathogenesis--what we know and what we don't know[J]. J Infect Dis. 2014, 209(7):982-955. doi: 10.1093/infdis/jit639 pmid: 24626533
[10]	Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada[J]. J Pediatr. 2003, 143(5):576-581. doi: 10.1067/S0022-3476(03)00365-2
[11]	Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants[J]. Clin Infect Dis. 2008, 47(3):328-338. doi: 10.1086/591413
[12]	Son S, Thamlikitkul V, Chokephaibulkit K, et al. Prospective multinational serosurveillance study of Bordetella pertussis infection among 10- to 18-year-old Asian children and adolescents[J]. Clin Microbiol Infect, 2019, 25(2): 250.e1-250.e7. doi: 10.1016/j.cmi.2018.04.013
[13]	van der Lee S, Stoof SP, van Ravenhorst MB, et al. Enhanced Bordetella pertussis acquisition rate in adolescents during the 2012 epidemic in the Netherlands and evidence for prolonged antibody persistence after infection[J]. Euro Surveill, 2017, 22(47):17-00011.
[14]	Hallander HO, Gustafsson L, Ljungman M, et al. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose[J]. Vaccine, 2005, 23(46-47):5359-5364. pmid: 16051400
[15]	Hallander HO, Ljungman M, Storsaeter J, et al. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children[J]. APMIS. 2009, 117(11):797-807. doi: 10.1111/j.1600-0463.2009.02530.x pmid: 19845530

组别	例数	PT-IgG			χ²值	P
组别	例数	<20 IU·mL^-1	20~80 IU·mL^-1	≥80 IU·mL^-1	χ²值	P
未接种组采样时病程					43.45	<0.001
≤14d	115	103（89.6）	9（7.8）	3（2.6）
15~21d	106	72（67.9）	26（24.5）	8（7.5）
>21d	92	49（53.3）	21（22.8）	22（23.9）
接种组采样时病程					21.80	<0.001
≤14d	116	75（64.7）	26（22.4）	15（12.9）
15~21d	127	49（38.6）	41（32.3）	37（29.1）
>21d	82	34（41.5）	21（25.6）	27（32.9）

组别	≤3月龄	~6月龄	~9月龄	~12月龄	>12月龄	H值	P
未接种组
例数	131	139	20	13	10
PT-IgG/IU·mL^-1	2.60(0.07~22.46)	2.55(0.03~29.11)	15.39(0.16~51.18)	5.41(0.23~63.36)	0.27(0.00~6.28)	4.12	0.390
接种组
例数	-	107	69	38	111
PT-IgG/IU·mL^-1	-	15.15(1.38~54.00)	24.22(4.52~59.09)	23.18(1.38~106.7)	36.09(0.00~123.39)	5.72	0.126

组别	采样时病程	重症组		普通组		Z值	P
组别	采样时病程	例数	PT-IgG/IU·mL^-1	例数	PT-IgG/IU·mL^-1	Z值	P
未接种组	≤14d	14	0.03(0.00~1.93)	101	0.47(0.00~4.26)	1.44	0.151
	15~21d	10	12.99(5.87~68.99)	96	4.53(0.01~30.41)	0.99	0.323
	>21d	7	12.66(0.00~44.24)	85	18.83(0.77~82.72)	1.22	0.222
H值			7.99		35.23
P			0.018		<0.001
接种组	≤14d	1	0.07	115	8.59(0.70~45.34)	-	-
	15~21d	4	11.27(1.80~106.54)	123	34.26(2.01~96.81)	0.84	0.403
	>21d	2	56.24, 16.65	80	35.97(8.50~108.94)	-	-
H值			-		17.92
P			-		<0.001

Analysis of related factors of serum PT-IgG concentration in children with pertussis diagnosed by etiology

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 15

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZHANG Haiqing, CHEN Yanping, ZHANG Jin. Research progress of Mycoplasma pneumoniae vaccine [J]. Journal of Clinical Pediatrics, 2022, 40(8): 634-640.
[2]	GUI Mingzhu, LIU Yingli, DING Afeng, XIE Xiaotian. Clinical characteristics and influencing factors of SARS-CoV-2 Omicron variant infection in children [J]. Journal of Clinical Pediatrics, 2022, 40(10): 765-769.
[3]	BI Fangchuan. Research progress on enterovirus 71 vaccines [J]. Journal of Clinical Pediatrics, 2021, 39(5): 391-.
[4]	LI Xiaoying. Progress in diagnosis and treatment of abnormal reactions after BCG vaccination in children [J]. Journal of Clinical Pediatrics, 2020, 38(7): 554-.
[5]	WU Xiaoying, GAN Chuan. Analysis of risk factors of death in severe pertussis in infant [J]. Journal of Clinical Pediatrics, 2020, 38(6): 432-.
[6]	Zhang Guangli, Tian Xiaoyin, Gu Ruixue, et al. Analysis of clinical characteristics of children with severe pertussis in Chongqing [J]. Journal of Clinical Pediatrics, 2020, 38(2): 134-.
[7]	GAN Chuan, WU Xiaoying, XU Hongmei, et al. Effect of exchange transfusion in the treatment of pertussis in children with hyperleukocytemia [J]. Journal of Clinical Pediatrics, 2020, 38(10): 721-.
[8]	LIU Yanqin, WANG Li, YU Huafeng, et al. The level of antibodies to Bordetella pertussis among pregnant women and their newborns in Jinan area [J]. Journal of Clinical Pediatrics, 2020, 38(10): 726-.
[9]	HU Sile. Efficacy, timing and safety of pneumococcal vaccination in preterm infants [J]. , 2018, 36(9): 711-.
[10]	LI Xiaowen, WANG Xueqiu, LI Luquan. The clinical feature of neonatal pertussis [J]. , 2017, 35(3): 170-.
[11]	XU Mei, DENG Jikui. Clinical characteristics of pertussis in 17 neonates [J]. , 2016, 34(9): 667-.
[12]	YU Feng. Rotavirus molecular epidemiology and vaccine protection efficiency in China [J]. , 2015, 33(2): 191-.
[13]	LI Xiaoling，SUN Lirong. BCG HSP70 gene transfection and its effect on immunogenicity of murine lymphocytic leukemia [J]. , 2015, 33(2): 174-.
[14]	LI Xiaoling,LIU Chunlei,SUN Lirong . Preparation of HL-60 cell vaccine expressing BCG-HSP70 and its anti-leukemia effect [J]. , 2014, 32(5): 462-466.
[15]	REN Sisi,WANG Dongfang,ZHONG Zhaohui . Immunogenicity and safety of the acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenza type b conjugate vaccine (DTaP-IPV/Hib combined vaccine): a meta-analysis [J]. , 2014, 32(3): 271-277.